Power Law company profile

Lumos Pharma

Biotech & Life Sciences · Ames, United States · Founded 1999 · IPO 2011 Colt

NewLink Genetics, a biopharmaceutical company, develops therapeutic and diagnostic agents for patients with cancer and infectious diseases

Valuation

$38M

Market cap · 2026

Revenue

$40M

Latest reported FY

Featured in $1B+ revenueColt · Power Law growth-stage

Investors

3 investors on Lumos Pharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 3 investors entered at this stage

Chicagoland Investors

Ames Seed Capital

Iowa Capital Management

Global footprint

Where Lumos Pharma has talent and traffic

Workforce by country

🇺🇸 United States · Ames HQ

Book a demo for the full country breakdown

Web traffic by country

1.8K monthly visits
across markets

🇺🇸 United States66.7%

🇹🇷 Turkey16.7%

🇻🇳 Vietnam11.1%

🇹🇭 Thailand5.6%

Top 4 markets shown

Market sentiment

What the market is saying about Lumos Pharma

An AI-synthesized read of the highest-engagement posts about Lumos Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Lumos Pharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles